½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1531039

Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2034³â)

Insulin-like Growth Factors Market (Type: Mechano Growth Factor, Somatomedin C, and IGF 1; and End-user: Hospitals and Medical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 143 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀå - Á¶»ç ¹üÀ§

TMRÀÇ Á¶»ç º¸°í¼­ "Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ¼¼°è ½ÃÀå"Àº 2024³âºÎÅÍ 2034³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ ¾ò±â À§ÇØ °ú°Å»Ó¸¸ ¾Æ´Ï¶ó ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¸¦ Á¶»çÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼­´Â 2024³âÀ» ±âÁØ ¿¬µµ·Î, 2034³âÀ» ¿¹Ãø ¿¬µµ·Î ÇÏ¿© 2018³âºÎÅÍ 2034³â±îÁöÀÇ ¼¼°è Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀåÀÇ ¼öÀÍ°ú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ 2024³âºÎÅÍ 2034³â±îÁö ¼¼°è Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀåÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR %)À» Á¦½ÃÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ ÅëÇØ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼­ ¾Ö³Î¸®½ºÆ®´Â ÁÖ¿ä ¿ÀÇǴϾ𠸮´õ, ¾÷°è ¸®´õ, ¿ÀÇǴϾð ¸ÞÀÌÄ¿¸¦ ´ë»óÀ¸·Î ÀÎÅͺ並 ÁøÇàÇß½À´Ï´Ù. 2Â÷ Á¶»ç¿¡¼­´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ÀÚ·á, ¿¬·Ê º¸°í¼­, º¸µµÀÚ·á, °ü·Ã ÀÚ·á µîÀ» Âü°íÇÏ¿© Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀåÀ» Ãß·ÐÇß½À´Ï´Ù.

½ÃÀå ½º³À¼¦
2023³â ½ÃÀå ±Ô¸ð 2¾ï 7,440¸¸ ´Þ·¯
2034³â ½ÃÀå ±Ô¸ð 5¾ï 1,140¸¸ ´Þ·¯
CAGR 5.87%

ÀÌ º¸°í¼­´Â ¼¼°è Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀåÀÇ °æÀï ȯ°æÀ» Á¶»çÇÏ°í ÀÖ½À´Ï´Ù. ¼¼°è Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÌ È®ÀεǾúÀ¸¸ç, °¢ ±â¾÷µéÀº ´Ù¾çÇÑ ¼Ó¼ºÀ¸·Î ÇÁ·ÎÆÄÀϸµµÇ¾ú½À´Ï´Ù. ȸ»ç °³¿ä, À繫 »óÅÂ, ÃÖ±Ù µ¿Çâ, SWOT µîÀº ¼¼°è Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ ½ÃÀåÀÇ ±â¾÷µéÀÌ ÀÌ º¸°í¼­¿¡¼­ Á¦°øÇÏ´Â ¼Ó¼ºÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °¡Á¤°ú Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼Ò°³
  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ¼¼°èÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø, 2020-2034³â

Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®

  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ÁÖ¿ä Á¦Ç°/ºê·£µå ºÐ¼®
  • ÁÖ¿ä M&A
  • COVID-19¿¡ ÀÇÇÑ »ê¾÷¿¡ ´ëÇÑ ¿µÇâ

Á¦6Àå ¼¼°èÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Çüº°

  • ¼Ò°³¿Í Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú¡¤¹ßÀü
  • ½ÃÀå ±Ý¾× ¿¹Ãø : À¯Çüº°, 2020-2034³â
    • ¸ÞÄ«³ë ¼ºÀåÀÎÀÚ
    • ¼Ò¸¶Æ®¸Þµò C
    • IGF 1
  • ½ÃÀå ¸Å·Â ºÐ¼® : À¯Çüº°

Á¦7Àå ¼¼°èÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼Ò°³¿Í Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú¡¤¹ßÀü
  • ½ÃÀå ±Ý¾× ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
    • º´¿ø
    • ÀÇ·á ¼¾ÅÍ
  • ½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦8Àå ¼¼°èÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ±Ý¾× ¿¹Ãø : Áö¿ªº°, 2020-2034³â
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°

Á¦9Àå ºÏ¹ÌÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦10Àå À¯·´ÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦12Àå ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦13Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦14Àå °æÀï »óȲ

  • ½ÃÀå ±â¾÷ - °æÀï ¸ÅÆ®¸¯½º(±â¾÷ °èÃþ°ú ±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ±â¾÷º°(2023³â)
  • ±â¾÷ °³¿ä
    • Boehringer Ingelheim International GmbH
    • Genervon Biopharmaceuticals LLC
    • Ascendis Pharma
    • Regulaxis SAS
    • MedImmune, LLC
ksm 24.09.03

Insulin-like Growth Factors Market - Scope of Report

TMR's report on the global insulin-like growth factors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global insulin-like growth factors market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insulin-like growth factors market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the insulin-like growth factors market.

Market Snapshot
Market Value in 2023US$ 274.4 Mn
Market Value in 2034US$ 511.4 Mn
CAGR5.87%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global insulin-like growth factors market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global insulin-like growth factors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global insulin-like growth factors market.

The report delves into the competitive landscape of the global insulin-like growth factors market. Key players operating in the global insulin-like growth factors market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global insulin-like growth factors market profiled in this report.

Key Questions Answered in Global insulin-like growth factors Market Report:

  • What is the sales/revenue generated by insulin-like growth factors across all regions during the forecast period?
  • What are the opportunities in the global insulin-like growth factors market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Insulin-like Growth Factors Market - Research Objectives and Research Approach

The comprehensive report on the global insulin-like growth factors market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global insulin-like growth factors market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global insulin-like growth factors market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Insulin-like Growth Factors (IGFs) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Insulin-like Growth Factors (IGFs) Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Insulin-like Growth Factors (IGFs) Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2020-2034
    • 6.3.1. Mechano Growth Factor
    • 6.3.2. Somatomedin C
    • 6.3.3. IGF 1
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Insulin-like Growth Factors (IGFs) Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by End-user, 2020-2034
    • 7.3.1. Hospitals
    • 7.3.2. Medical Centers
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global Insulin-like Growth Factors (IGFs) Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2020-2034
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Insulin-like Growth Factors (IGFs) Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Type, 2020-2034
    • 9.3.1. Mechano Growth Factor
    • 9.3.2. Somatomedin C
    • 9.3.3. IGF 1
  • 9.4. Market Value Forecast, by End-user, 2020-2034
    • 9.4.1. Hospitals
    • 9.4.2. Medical Centers
  • 9.5. Market Value Forecast, by Country, 2020-2034
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Type
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe Insulin-like Growth Factors (IGFs) Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type, 2020-2034
    • 10.3.1. Mechano Growth Factor
    • 10.3.2. Somatomedin C
    • 10.3.3. IGF 1
  • 10.4. Market Value Forecast, by End-user, 2020-2034
    • 10.4.1. Hospitals
    • 10.4.2. Medical Centers
  • 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Type
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Insulin-like Growth Factors (IGFs) Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type, 2020-2034
    • 11.3.1. Mechano Growth Factor
    • 11.3.2. Somatomedin C
    • 11.3.3. IGF 1
  • 11.4. Market Value Forecast, by End-user, 2020-2034
    • 11.4.1. Hospitals
    • 11.4.2. Medical Centers
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Type
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America Insulin-like Growth Factors (IGFs) Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
    • 12.2.1. Mechano Growth Factor
    • 12.2.2. Somatomedin C
    • 12.2.3. IGF 1
  • 12.3. Market Value Forecast, by End-user, 2020-2034
    • 12.3.1. Hospitals
    • 12.3.2. Medical Centers
  • 12.4. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Type
    • 12.5.2. By End-user
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Insulin-like Growth Factors (IGFs) Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Type, 2020-2034
    • 13.3.1. Mechano Growth Factor
    • 13.3.2. Somatomedin C
    • 13.3.3. IGF 1
  • 13.4. Market Value Forecast, by End-user, 2020-2034
    • 13.4.1. Hospitals
    • 13.4.2. Medical Centers
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Type
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2023)
  • 14.3. Company Profiles
    • 14.3.1. Boehringer Ingelheim International GmbH
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Genervon Biopharmaceuticals LLC
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Ascendis Pharma
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Regulaxis SAS
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. MedImmune, LLC
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦